<DOC>
	<DOCNO>NCT01497873</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Belotecan administer 5 day every 3 week comparison Topotecan Patients relapse small cell lung cancer .</brief_summary>
	<brief_title>Study Assess Belotecan Topotecan Daily Schedule Relapsed Small Cell Lung Cancer ( SCLC ) Patients</brief_title>
	<detailed_description>A Phase Ⅱb , Randomized , Open , Parallel-Group , Multi-Center Trial Assess Efficacy Safety Belotecan ( CamtoBell inj . ) Topotecan Patients Relapsed Small Cell Lung Cancer</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Belotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>At least 18 year age Histological cytological diagnosis SCLC Limited disease ( LD ) Extensive disease ( ED ) time study entry Recurrent progressive SCLC ≥ 90 day duration response firstline therapy Measurable disease define RECIST criterion ECOG Performance Status 0 , 1 , 2 Life expectancy &gt; 3 month Adequate bone marrow , Renal , Hepatic reserve : absolute neutrophil ( segmented band ) count ( ANC ) ≥ 1500 cells/μL platelet count ≥ 100,000 cells/μL hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 X ULN Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.0 X ULN Alkaline Phosphatase ( ALP ) ≤ 2.0 X ULN Serum creatinine &lt; 1.5mg/dL calculated creatinine clearance &gt; 60mL/min Signed write informed consent Active infection Symptomatic brain lesion Any type cancer previous 5 year Severe concurrent disease Prior anticancer therapy within 4 week enroll Active pregnancy test Pregnant nursing woman Participation investigational drug study within 28 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Belotecan</keyword>
	<keyword>Topotecan</keyword>
</DOC>